Letter
Dabigatran thrombotic events
Thrombotic events after discontinuing dabigatran: rebound or resumption?
Cite this as:
BMJ
2012;345:e4469
- Katie M Thorne, medical registrar1,
- Stephen Dee, medical consultant2,
- Sisira Jayathissa, medical consultant2
- 1Palliative Care Centre, Wellington Hospital, Wellington, New Zealand
- 2Medical Department, Hutt Hospital, Wellington, New Zealand
- Katie.Thorne{at}hyms.ac.uk
The REMODEL trial has suggested that stopping dabigatran does not produce a rebound thrombotic effect.1 2 However, others have raised the possibility of this.3
Such rebound pro-thrombotic activity and clusters of thrombotic events have been reported with heparin and older anti-thrombotic drugs, and concerns are now being expressed about the newer anticoagulants, including the factor Xa inhibitor, rivaroxaban, and oral direct thrombin …
Sign in
Article access
Article access for 1 day
Purchase this article for £20 $30 €32*
The PDF version can be downloaded as your personal record
Social bookmarking